InMode (INMD) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 May, 2026Executive summary
Q1 2026 revenue reached $82 million, up 5% year-over-year, with significant U.S. contribution and early signs of stabilization.
Non-GAAP net income was $15.9 million ($0.25 per diluted share); GAAP net income was $11.6 million ($0.18 per share), both down from Q1 2025.
Global operations span 103 countries, supported by a direct sales force of 298 representatives and a strong brand in minimally-invasive aesthetic and wellness solutions.
New North American leadership and unified structure implemented, with ongoing organizational restructuring in North America and Europe.
CFO Yair Malca and Board Chair Dr. Michael Anghel resigned, with Dr. Hadar Ron appointed Interim Chair.
Financial highlights
Q1 2026 revenue was $82 million, up 5% year-over-year; non-GAAP gross margin was 75% (down from 79%); GAAP gross margin was 75% (down from 78%).
Non-GAAP net income was $15.9 million; GAAP net income was $11.6 million.
Cash, equivalents, and marketable securities totaled $537.2 million as of March 31, 2026.
Share repurchases totaled $127.4 million in 2025 and $52.7 million year-to-date in 2026, representing 3.86 million shares.
Operating cash flow for Q1 2026 was $15.4 million.
Outlook and guidance
FY 2026 revenue guidance: $365–$375 million.
Non-GAAP gross margin guidance: 74%–76%.
Non-GAAP operating income guidance: $73–$78 million; non-GAAP EPS guidance: $1.33–$1.38.
Corporate tax rate expected to remain at 7.5–10% due to Israeli tax benefits.
Gross margin expected to remain stable at 74–75% through the year.
Latest events from InMode
- Growth from new products offsets margin pressure; global expansion and R&D drive future potential.INMD
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - Manufacturing and logistics face disruption, but strategic buybacks and global expansion continue.INMD
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Flat top line expected in 2026, with new products and restructuring to drive future recovery.INMD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Q4 revenue up 6% to $103.9M, FY sales down 6%, 2026 stable with new launches and strong cash.INMD
Q4 202510 Feb 2026 - Q2 revenue fell 36.5% to $86.4M; guidance cut, but new launches and buybacks support outlook.INMD
Q2 20242 Feb 2026 - Strong innovation and global expansion offset U.S. softness; M&A remains top capital priority.INMD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Product refresh, robust margins, and innovation drive growth amid macro headwinds and financing shifts.INMD
Jefferies Global Healthcare Conference31 Jan 2026 - 2024 buyback, international expansion, and new product upgrades drive long-term growth focus.INMD
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue rose to $130.2M, but margins and guidance declined amid macro headwinds.INMD
Q3 202417 Jan 2026